Infectious Disease & Vaccines

Unrelenting science

Persistence and determination are our mantras in the face of bacterial, fungal and viral infections—together accounting for significant threats to public health and rising healthcare costs. We are leaders in this area of research, relentlessly exploring the role of biologics, small molecules and vaccines to address these challenges.


Four years ago, the European Commission called for “unprecedented collaborative research and development efforts to bring new antibiotics to patients.” This included the launch of the sixth Innovative Medicines Initiative (IMI) Call for Proposals in 2012 as part of a program titled New Drugs 4 Bad Bugs, or ND4BB. Less than a year later, the COMBACTE consortium, an unparalleled public-private partnership that includes academia and industry, was formed.

Our Pipeline

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • MEDI2070 Crohn’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

Infectious Disease Publications


Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.